Goldman Sachs’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Goldman Sachs’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-153,020	Closed	-$15K	–	7314
2016 Q3	$15K	Sell	153,020 -46,213	-23%	-$10.1K	﹤0.01%	6822
2016 Q2	$74K	Buy	199,233 +60,559	+44%	+$23K	﹤0.01%	6269
2016 Q1	$53K	Sell	138,674 -232,060	-63%	-$95.6K	﹤0.01%	6406
2015 Q4	$145K	Sell	370,734 -591,286	-61%	-$280K	﹤0.01%	5936
2015 Q3	$553K	Buy	+962,020	New	+$493K	﹤0.01%	5039
2015 Q1	–	Sell	-14,900	Closed	-$12K	–	7457
2014 Q4	$12K	Sell	14,900 -277,951	-95%	-$254K	﹤0.01%	7034
2014 Q3	$299K	Sell	292,851 -11,538	-4%	-$11.2K	﹤0.01%	5760
2014 Q2	$262K	Buy	+304,389	New	+$365K	﹤0.01%	5993

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Goldman Sachs's PVCT Position: Q4 2016 in Review

Goldman Sachs sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 153,020 shares — an estimated $15K sold.

Goldman Sachs first reported a position in PVCT in Q2 2014 and held it in 8 quarters. The position peaked at $553K in Q3 2015. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Goldman Sachs reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 153,020 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $15K.
Goldman Sachs first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 8 quarters.
Goldman Sachs's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $553K in Q3 2015.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.